Kornimate/medical-research-clean huggingface dataset:
near horizontal heterophoria in chinese children

Conditions: Myopia, Progressive

Summary: this study aimed to assess the association of refraction and axial length with near-horizontal heterophoria in a large population-based study of school-aged chinese children. the study makes a significant contribution to better know the etiology of myopia progression and ocular axial length development. further, this study will be of interest to the readership of your journal because its noteworthy finding and which could contribute to guide recommendations for targeted interventions to slow myopia progression.

myopia is becoming a global public health burden which is believed to have a multifactorial etiology. the relationship between heterophoria and refraction remains controversial. we describe the association of refraction and axial length (al) with heterophoria in a large population-based study of school-aged chinese children. eleven thousand thirteen elementary school children grades 1-6, were included in this school-based, cross-sectional study. near phoria data was quantified by using maddox rod test and prism at 33 cm. children in each grade level were sorted into three groups based upon phoria: 1) those with more than six prism diopters (pd) exophoria, 2) those with zero to six pd exophoria, and 3) those with any amount of esophoria. autorefraction was measured by autorefractor (topcon kr8900, japan) and al was measured by optical biometer al-scan (nidek al-scan, japan). a generalized additive model (gam) was applied with a gaussian link to explore the association between the refractive error or axial length and heterophoria. an additional age-adjusted model was also employed for analysis.

Eligibility criteria:
inclusion criteria: * ages of 6 and 13 years * chinese school children exclusion criteria: * subjects with eye diseases or strabismus
online "pain, stress & emotions" class in chronic pain

Conditions: Chronic Pain

Summary: members with chronic pain will be invited to participate in a 2-hour zoom-delivered pain psychology class entitled "pain, stress, \& emotions". surveys are completed at baseline (prior to the online class), a satisfaction survey is completed after the class, and post-treatment surveys completed 2, 4, 8, and 12 1weeks after class attendance.


Eligibility criteria:
inclusion criteria: * chronic pain condition (pain \> 3 months) * access to the internet * english fluency exclusion criteria: * ongoing legal action or disability claim * cognitive impairment, non-english speaking, or psychological factors that would preclude comprehension of material and/or full participation in the study.
an open-label extension study for patients with duchenne muscular dystrophy who participated in studies of srp-5051 (vesleteplirsen)

Conditions: Muscular Dystrophy, Duchenne

Summary: the purpose of this extension study is to evaluate the safety, tolerability, and pharmacokinetics of repeat administrations of srp-5051 (vesleteplirsen) in participants with duchenne muscular dystrophy (dmd) who participated in studies of srp-5051.


Eligibility criteria:
inclusion criteria: • has completed a study of srp-5051 and continues to meet the eligibility criteria of study 5051-102. exclusion criteria: * initiation or change of dosing (except for modifications to accommodate changes in weight or changes in standard of care) since completing a study administering srp-5051 and while participating in this study for any of the following: angiotensin converting enzyme (ace) inhibitors, angiotensin receptor blocking agents (arbs), beta-blockers, potassium and steroids\*. * requires antiarrhythmic and/or diuretic therapy for heart failure. * use of any herbal medication/supplement containing aristolochic acid. * treatment with any experimental therapy since entering original study or any experimental gene therapy for the treatment of dmd at any time. * participation in an interventional clinical trial since completing original study. other inclusion/exclusion criteria apply. \* the dose of steroids must remain constant except for modifications to accommodate changes in weight.

Keywords: duchenne muscular dystrophy exon skipping dmd exon 51 ambulatory pediatric nonambulatory peptide-conjugated phosphorodiamidate morpholino oligomer (ppmo) duchenne
acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients

Conditions: Breast Cancer; Peripheral Neuropathy

Summary: the purpose of this study is to find out the effects of acupuncture on reducing nerve damage. acupuncture is a medical technique of inserting very thin needles into the "energy points" on the body with the aim to restore health and well-being. it has been used widely to treat pain, such as lower back pain and joint pain. in this study the investigators will assess if acupuncture can be used to ease the pain, tingling and numbness that may be caused by chemotherapy and improve quality of life during chemotherapy.


Eligibility criteria:
inclusion criteria: screening phase: * age 21 or older. * histologically proven stage i-iii carcinoma of the breast. * plan to receive adjuvant or neoadjuvant chemotherapy that includes weekly paclitaxel. * eastern cooperative oncology group performance status 0-2 (see appendix b). * the patient is aware of the nature of his/her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form. * proficiency in english with the ability to speak and read english. exclusion criteria: * known metastatic (stage iv) breast cancer involvement. * pre-existing peripheral neuropathy within 28 days of screening consent * currently taking anti-neuropathy medication such as gabapentin, pregabalin, duloxetine, or glutamine. intervention phase: * age 21 or older. * histologically proven stage i-iii carcinoma of the breast. * receiving adjuvant or neoadjuvant chemotherapy that includes a taxane. * eastern cooperative oncology group performance status 0-2 * the patient is aware of the nature of his/her diagnosis, understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form. * proficiency in english with the ability to speak and read english * while on neurotoxic chemotherapy, has developed nci-ctc grade 2 cipn exclusion criteria: * known metastatic (stage iv) breast cancer involvement. * pre-existing peripheral neuropathy within 28 days of screening consent. * currently taking anti-neuropathy medication such as gabapentin, pregabalin, duloxetine, or glutamine.

Keywords: acupuncture paclitaxel 15-011
the effect of omalizumab on allergic rhinitis symptoms: a comparative study

Conditions: Allergic Rhinitis

Summary: we aimed to evaluate the usability and efficacy of omalizumab in allergic rhinitis and its potential as an alternative treatment option.

the study was conducted to determine the effectiveness of omalizumab on symptoms in patients diagnosed with allergic rhinitis and to compare it with current medical treatment options.

Eligibility criteria:
inclusion criteria: * those who gave informed consent and wanted to participate in the study and did not have any additional systemic or nasal diseases were included. exclusion criteria: * under 18 years old, * over 65 years old, * with systemic comorbidities (diabetes mellitus, hypertension, chronic renal failure, hypothyroidism, etc.) * patients with rhinosinusitis, nasal polyps, nasal septal deviation, tumors, smoking and nasal surgery, and non-compliant patients were excluded from this study.

Keywords: allergic rhinitis omalizumab
single leg cycling in copd: knowledge translation to pulmonary rehabilitation

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: pulmonary rehabilitation (pr) with supervised exercise training is a key part of care for patients with chronic lung disease (copd). patients can improve their shortness of breath, walking distance and quality of life. however, many patients do not improve their overall fitness. they are too breathless to train at a high enough intensity. in a laboratory training study, patients with copd improved their overall fitness by using single leg cycling. despite this knowledge, single leg cycling has not been used clinically. the objective of this project is to use and assess single leg cycling in a clinical setting. single leg cycling can be incorporated into a clinical service (replacing traditional two legged cycling) as the predominant aerobic training strategy, resulting in improvements in cardio-respiratory fitness (peak oxygen uptake).


Eligibility criteria:
inclusion criteria: * patients with copd referred for pulmonary rehabilitation exclusion criteria: * unstable cardiac disease * any neurological or orthopaedic condition that would make cycling difficult

Keywords: copd exercise cycling single leg pulmonary rehabilitation
home reported outcomes in pnh

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Summary: the study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (hrqol) experienced by pnh patients. by primarily utilizing home reported outcomes (hro) data on symptom burden and treatment usage, supplemented with patient-reported outcome (pro) measures, the study seeks to establish a new real-world data (rwd) source to understand symptom variability and hrqol among pnh patients, including those receiving orally administered iptacopan.

the study will be prospective and observational, conducted over an initial period of six months per individual from the point of study enrollment. participants will utilize the folia mobile app to enroll, consent, and complete all study activities. a hybrid recruitment method of clinic referrals and community referrals will be employed to identify participants, who will be asked to track routine treatment, symptoms, changes in treatment plans, and hrqol using the folia health mobile app. monthly survey check-ins will be conducted to capture additional data inputs, with the possibility of integrating electronic health record (ehr) and/or claims data.

Eligibility criteria:
inclusion criteria: study participants eligible for inclusion in this study must meet all of the following criteria: * aged 18 or older * us-based with a proficient understanding of and ability to read the english language * any patient with a diagnosis of pnh, regardless of symptom or treatment history exclusion criteria: study participants who do not fit all inclusion criteria listed above are unable to participate in this study. outside of required inclusion criteria, there are no other exclusion criteria in order to meet the exploratory nature of the primary endpoint.

Keywords: paroxysmal nocturnal hemoglobinuria pnh home reported outcomes hro patient-reported outcome pro real-world data iptacopan
study in intensive care patients regarding the effect of inhaled ap-301 after primary graft dysfunction after lung transplantation

Conditions: PGD Primary Graft Dysfunction

Summary: the purpose of this study is to investigate the effect of orally inhaled ap-301 on primary graft dysfunction after lung transplantation.


Eligibility criteria:
inclusion criteria: * being a male or female recipient on the akh's waiting list for primary single or double lutx * pgd score ≥ 1 within 72 hours after lutx * informed consent is available exclusion criteria: * history of clinically relevant allergies or idiosyncrasies to ap301 or any other inactive ingredient(s) of the investigational product * postoperative ecmo support * paediatric /adolescent recipients (\< 18 years) * lobar transplantation * retransplantation * combined solid organ transplants * participation in other drug trials

Keywords: peptide
intracranial recordings to characterize action regulation mechanisms

Conditions: Parkinson Disease

Summary: humans can rapidly regulate actions according to evolving environmental demands, however, impairments of action regulation have been identified across a number of neurological disorders including parkinson's disease (pd). a key component of action regulation is action inhibition that occurs when stopping unwanted or inappropriate actions. there is mounting evidence that action inhibition also plays a critical part in selecting between competing alternative actions and switching to new actions in response to environmental changes. the investigators hypothesize that stop circuitry (involving frontal-subthalamic nucleus (stn) pathways) are involved in inhibiting unselected actions during action selection with competing alternatives (in the absence of overt stopping) and that switching motor plans also engages stopping circuitry (involving prefrontal-stn pathways) for cancelling the ongoing action, before changing to new one. the overall goal is to delineate the neural circuitry underlying a broad array of action regulation functions that involve inhibitory control, how these functions interrelate, and how they are implemented within brain networks. in this research, the investigator will take advantage of the unique opportunity provided by awake deep brain stimulation surgery to learn more about how the brain functions in a diseased state and how deep brain stimulation changes these networks to make movement more normal. the investigator will simultaneously assess cortical and subcortical electrophysiology in relation to clinical symptoms and behavioral measures and in response to deep brain stimulation in patients undergoing deep brain stimulation (dbs) implantation surgery.


Eligibility criteria:
inclusion criteria: * age 18 years or older. * diagnosis of parkinson's disease (rigid-akinetic subtype or tremor-dominant) based on presence of at least 2 cardinal pd features (tremor, rigidity, or bradykinesia). * clinical indication and decision to proceed with subthalamic nucleus deep brain stimulation implantation. * l-dopa responsive with clearly defined "on" periods, with at least 30% improvement in updrs iii scores on vs off medications (with documented on updrs iii scores). * willingness and ability to cooperate during conscious operative procedure for up to 30 minutes. * preoperative mri without evidence of cortical or subdural adhesions or vascular abnormalities. exclusion criteria: * patients with recent use (within one week) of anticoagulant or antiplatelet agent use. * neurocognitive testing indicating amnestic cognitive deﬁcits (moca \< 24).
a study to investigate lp352 in children and adults with developmental and epileptic encephalopathy (dee)

Conditions: Developmental and Epileptic Encephalopathy

Summary: this (deep ole study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (pk) of lp352 in the treatment of seizures in children and adults with dee who completed study lp352-301 or lp352-302. the study consists of 3 main phases: screening, titration period and maintenance period, followed by a taper period and follow-up. the total duration of the study will be approximately 14 months.


Eligibility criteria:
inclusion criteria: * the participant has satisfactorily completed study lp352-301 or lp352-302 visit 8, and who, in the opinion of the investigator, may benefit from continued lp352 administration. * diagnosis of dee that includes dravet syndrome (ds), lennox-gastaut syndrome (lgs), or dee other (as defined and evaluated in study lp352-301 or lp352-302). * has at least one reliable and consistent parent, legal guardian, or caregiver during the study. * the participant or legal representative must be willing and able to provide written informed consent * the participant, parent, or caregiver is willing and able (in the judgment of the investigator) to comply with completion of the diaries throughout the study. exclusion criteria: * the participant is receiving exclusionary medications. * current use of any cannabis product or cannabidiol that is not in oral solution/capsule/tablet form, not obtained from a government-approved dispensary, or containing ≥50% delta-9-tetrahydrocannabinol (thc). * the participant has unstable, clinically significant neurologic (other than the disease being studied, eg, recurrent strokes), psychiatric, cardiovascular (eg, pulmonary arterial hypertension, cardiac valvulopathy, orthostatic hypotension/tachycardia) pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, hematopoietic, or endocrine disease or other abnormality which may impact the ability of the participant to participate or potentially confound the study results. * the participant is unable or unwilling to comply with any of the study requirements or timelines.

Keywords: developmental and epileptic encephalopathy lp352 bexicaserin seizures deep ole antiseizure medications epilepsy neurodevelopmental disorders dravet syndrome lennox-gastaut syndrome
effects of oxy111a in primary and secondary hepato-pancreato-biliary neoplasm

Conditions: Pancreatic Neoplasms; Hepatocellular Cancer; Cholangiocarcinoma; Colorectal Neoplasms

Summary: the purpose of the study is to evaluate whether the novel anti-cancer drug oxy111a is safe and tolerated in patients with primary and secondary hepato-pancreato-biliary and gastrointestinal neoplasia as measured by exploring the maximum tolerated dose (mtd). at level of mtd, additional patients will be included aimed for assessing the efficacy profile in these neoplasia entities.

the imp oxy111a counteracts hypoxia-induced tumor aggressiveness showing decreased tumor burden and increased survival in five different animal solid tumor models both applied as monotherapy and increased beneficial effects when followed by standard chemotherapy. the unique ability of the imp counteract hypoxic tumor behaviour along with its non-toxic side effects tested both in animals and healthy volunteers is of outmost interest to explore in patients with solid tumors. the study seeks primarily to determine the safety and tolerability of oxy111a in patients with primary and secondary hepato-pancreato-biliary and gastrointestinal neoplasia as measured by exploring the mtd in a conservative 3+3 dose escalation schedule. the window for dlt assessment is from first dose of study drug until first dose of standard of care chemotherapy or 10 days following completion of last dose of study drug (whichever is shorter in duration). additionally, we will assess efficacy of oxy111a on decreasing tumor volume, metabolic activity, as well as circulatory tumor and angiogenic markers.

Eligibility criteria:
inclusion criteria: * study indication: patients diagnosed for non-resectable hepato-pancreato-biliary or gastrointestinal neoplasm * male and female patients ≥ 18 years of age * signed informed consent after being informed * eastern cooperative oncology group (ecog) performance status score of ≥ 2 at study entry. * a life-expectancy of \>3 months * adequate hematologic and renal function * use of effective contraception (per the institutional standard), if procreative potential exists * adequate recovery from recent surgery, chemotherapy, and radiation therapy. at least 28 days must have elapsed from major surgery, prior chemotherapy, prior treatment with an investigational agent or device, or prior radiation therapy (palliative radiation therapy is allowed) * accessible for treatment and follow-up. patients enrolled in this trial must be treated at the participating center exclusion criteria: * contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product * women who are pregnant or breast feeding

Keywords: hypoxia pancreatic neoplasms hepatocellular cancer cholangiocarcinoma colorectal neoplasms treatment
phase 4 field trial of the unicirc instrument with tissue adhesive

Conditions: Male Circumcision

Summary: this is a field trial of the unicirc instrument to excise the foreskin, plus use of cyanoacrylate tissue adhesive to seal the wound.


Eligibility criteria:
inclusion criteria: * men at least 18 years of age exclusion criteria: * poor general health * anatomical abnormalities that would complicate circumcision * bleeding disorder * ongoing infection * cannot attend followup visits

Keywords: circumcision hiv prevention surgical device cyanoacrylate tissue adhesive voluntary
histopathological, biochemical and electrophysiological evaluation of single or combined use of diode laser/steroid treatment on facial nerve injury

Conditions: Nerve Injury; Laser Therapy; Methylprednisolone; Facial Nerve Injuries

Summary: the objective of the study will be to investigate the effect of low-level diode laser therapy (lllt) and steroid on facial nerve injury. thirty five male wistar rat will randomly be divided into five groups: healthy control (hcg); damage control (dc); laser (lg); steroid (sg); and combined laser and steroid group (lsg). right facial nerve electromyography (emg) data will record after facial nerve damage done and before sacrification at 4th week.the results will be evaluated histopathologically, electrophysiologically and biochemically.

the animals will be randomly divided into two control groups, a healthy control group and a damaged control group, and three experimental groups; 7 rats were assigned to each group as follows; 1. healthy control group (hcg): seven rats will be included randomly in this group. no surgical/medical approach will be applied. emg measurements will betaken over the right facial nerve. 2. damaged control group (dcg): facial nerve injury will be created on the right facial nerve. no surgical/medical approach will be applied. emg measurements will be taken over the right facial nerve after the injury and after the four weeks of treatment. 3. laser group (lg): facial nerve injury will be created on the right facial nerve. lllt (low-intensity et al.) will be applied 3 times a week for 4 weeks postoperatively, at 830 nm with an optical power output of 30 mw, an energy density of 4 j/cm2, an irradiation area of 0.116 cm2 and an exposure time of 16 s per spot. emg measurements will be taken over the right facial nerve after the injury and after the four weeks of treatment. 4. steroid group (sg): facial nerve injury will be created on the right facial nerve. intraperitoneal methylprednisolone (1mg/kg/day) will be administered every day for 1 week postoperatively. emg measurements will be taken over the right facial nerve after the injury and after the four weeks of treatment. 5. laser+steroid group (lsg): facial nerve injury will be created on the right facial nerve. laser and steroid treatment will be applied in combination. emg measurements will be taken over the right facial nerve after the injury and after the four weeks of treatment.

Eligibility criteria:
inclusion criteria: -thirty-five male sprague-dawley rats weighing 200-300 g will be included the study exclusion criteria: -rats that are older than 6 months and are not healthy and have impaired facial motor functions will be excluded from the study.

Keywords: facial nerve injury steroid low level laser therapy nerve recovery